Expanding pharmaceutical industry at a rapid pace is significantly fueling the growth of the calcium lactate market

The Asia Pacific is expected to dominate the global calcium lactate market and this is attributed to the expanding end-user industries such as pharmaceuticals, agriculture/animal feed, and food processing industry. Also, the increasing population and growing disposable income of the consumer are again anticipated to propel the growth of the calcium lactate market. An increase in the fast-food consumption in the region is further fostering the growth of the market.

Expanding pharmaceutical industry at a rapid pace is significantly fueling the growth of the calcium lactate market. According to the Pharmaceutical Commerce, the global pharmaceutical market made $1.2 trillion in 2018. The market is expected to reach $1.5 trillion by 2023, at a growth rate of 4–5%. Also, the growing food &beverage industry as food &beverage is one of the major end-user of calcium lactate is again projected to foster the growth of the market. It is used as an additive in the preparation of various food such as bakery, dairy products, etc. Moreover, expanding food processing industry across South Asian countries such as Indonesia, Myanmar, and Taiwan is also fostering the growth of the market. Furthermore, it is also used as an acidity regulator in the agriculture/animal feed industry.

North America region is also one of the largest food &beverage markets and this is attributed to the increasing spending on the industry. According to the Economic Research Service U.S. Department of Agriculture, in 2019, food spending by U.S. consumers, businesses, and government entities totaled $1.77 trillion. Food away-from-home accounted for 54.8 percent of total food expenditures, up from 50.1 percent in 2009.

Calcium lactate or calcium carbonate is the compound formed by the breakdown of lactose in milk when it has sugar content. Calcium lactate can be separated into two states - acid and non-acid. The acid form is used in making milk and most of the products are derived from milk. The non-acid form is used more commonly and is derived from fruits, vegetables, sugarcane, and other food products. Some of the calcium supplements in the market contain both of the forms at an equal level. Calcium lactate serves as a source of energy and plays an important role in breaking down muscle tissues and other tissues in the body.

Phosphodiesterase Enzyme (PDE) Inhibitors Market becomes an investment hotspot after getting aroused by an elevated occurrence of erectile dysfunction

 

In March 2021, a group of researchers from Karolinska Institute, Stockholm, Sweden concluded the results of their clinical study claiming that the use of PDE5 (Phosphodiesterase type-5) inhibitor in treatment of erectile dysfunction can lower the occurrence of cardiovascular disorders. Additionally, in July 2021, the bio-pharmaceutical company, Arcutis Biotherapeutics, Inc., enrolled the first patient in its Phase III clinical trial on ARQ-154 for treatment of seborrheic dermatitis.

Phosphodiesterase inhibitors are highly effective in combating the adverse effects of Crohn's disease. Enzymes that prevent or regulate the action of Crohn's Disease in the intestines to prevent inflammation and promote the healthy functioning of the intestine. Various proprietary anti-inflammatory (NSAIDs) in the market today are effective in reducing pain and swelling associated with Crohn's and improving the patient's quality of life. Some NSAIDs inhibit the absorption of substances like fatty acids, cholesterol and phospholipids. Oral non-steroidal anti-inflammatory drugs (USIDs) like Aspirin, Ibuprofen and Naproxen are the commonly used NSAIDs for Crohn's disease.

Crohn's and ulcerative colitis are very common inflammatory bowel diseases affecting the large colon. Crohn's affects the lower portion of the small intestine and causes ulcers within the colon. Ulcerative colitis is an inflammatory bowel disease causing inflammation of the colon. Crohn's and ulcerative colitis are affected by a variety of gastrointestinal (GI) medications including sulfasalazine, balsalazide and vincristine.

Besides these two serious inflammatory bowel diseases, there are a number of other conditions that respond well to the use of inhibitors. Non-alcoholic steatohepatitis (NASH) is a condition where the protective mucus layer in the stomach is replaced with a villous lining from the outside of the body.

Rising drug abuse cases are leading to a surge in erectile dysfunction (ED) conditions in men amidst changing lifestyles, which, in turn, are creating positive growth prospects for the phosphodiesterase enzyme (PDE) inhibitors market. Plus, the amalgamation of factors such as hyperlipidemia, prostate cancer, high blood pressure, diabetes, testosterone insufficiency, and overweight is broadening the scope for the phosphodiesterase enzyme (PDE) inhibitors market. On the contrary, the complications associated with PDE inhibitors along with the advent of generic drugs can cause a serious dent in the progress of the phosphodiesterase enzyme (PDE) inhibitors market.

Throughout the globe, the phosphodiesterase enzyme (PDE) inhibitors market in the North American region is likely to propel at a scalable rate on the heels of rising incidences of chronic disease coupled with the increased healthcare expenditure. In parallel, the Asia Pacific is also proving to be fruitful for the phosphodiesterase enzyme (PDE) inhibitors market owing to the growing number of erectile dysfunction cases compounded with the hormonal deficiencies among the population.

Bio-Rad Laboratories significantly contributing to the growth of the cell and gene therapy market with launch of Droplet Digital PCR (ddPCR) platforms

 

The growing prevalence of cardiovascular disease and cancer around the globe is primarily propelling the growth of the cell and gene therapy market. According to the World Health Organization (WHO), May 2017, around 17.9 million people died due to cardiovascular disease in 2016 globally, which accounts for 31% of all worldwide deaths. According to the same source, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020.

North America is expected to hold the dominant position in the global cell and gene therapy market and this is attributed to the growing prevalence of neurological disorders in the region. According to the U.S. Pharmacist Journal, January 2018, annually, around 1.2 million adults are diagnosed with early symptoms of brain disorders, of which 21% are due to Alzheimer’s disease, and the total number of new cases of Parkinson’s disease and traumatic brain injuries are around 135 million in the U.S. Moreover, growing research and development activities in the field of cell and gene therapy is again fostering the growth of the market. According to the Catalyst report, in December 2018, around 289 novel cell and gene therapies were in development for a variety of diseases, of which around 111 medicines were for cancer and around 28 medicines were for cardiovascular disease.

The cell and gene therapy field is ripe with opportunities and potential. Advances in technology are ushering in a whole new era in treating disease through personalized health care. The field now stands at a crossroads as it struggles to keep up with advances in molecular biology and pharmaceutical manufacturing capacity. The field now stands at a fork in the road as it battles the relentless march of technology and what it can do to the cell and gene therapy field.

The cell and gene production programs currently in development will usher in a sea change in the way we treat our diseases.

Key Developments:

1. In April 2021, Bio-Rad Laboratories, Inc. a global marketer in life science research and clinical diagnostic products announced the launch of two products for the Droplet Digital PCR (ddPCR) platforms to support the development and manufacture of safe and effective cell and gene therapies.

2. In January 2021, Ixaka (formerly Rexgenero) Launches as an Integrated Cell and Gene Therapy Company. The Company’s shareholders have funded the business with over £40 million in financing

3. In April 2021, Bayer has announced that it has expanded its cell and gene capabilities through the addition of a Cell Therapy Launch Facility

4. In January 2020, Lonza announced the process development roadmap for cell and gene therapies